OpenAI Researcher Miles Wang Launches Drug Discovery AI Startup

A New Player in AI-Powered Drug Discovery

Miles Wang, an OpenAI researcher known for work on accelerating scientific and biological discovery through AI, is leaving the ChatGPT maker to launch his own startup. The focus: developing AI models specifically designed for drug discovery. According to sources familiar with his plans, several other OpenAI researchers are expected to join the venture.

The timing signals growing investor appetite for applying AI to life sciences challenges. Wang is in talks to raise approximately $200 million at a $2 billion valuation, with venture capital firm Lightspeed reportedly in discussions to lead the funding round. While the deal isn’t finalized and details could shift, the numbers underscore how seriously the investment community is taking this space.

Wang has disputed some of the reported figures and descriptions of his company but hasn’t provided alternative specifics. Lightspeed declined to comment.

The Crowded AI Drug Discovery Landscape

Wang’s entry into the market comes as major players are already raising staggering sums. Just this week, Chai Discovery, a two-year-old startup developing AI models that predict molecular interactions to identify new drugs, announced a $400 million raise at a $3.8 billion valuation. Notably, Chai’s co-founder Josh Meier also previously worked as a researcher at OpenAI.

Meanwhile, Google DeepMind’s spinout Isomorphic Labs, another AI drug discovery player, closed a $2.1 billion Series B round in May. The momentum is undeniable.

What sets Wang’s approach apart, according to a couple of sources who spoke with TechCrunch, is a potential focus on repurposing existing drugs. His startup may develop AI models that identify new applications for already-approved medications and even compounds that failed in previous trials. This strategy carries a significant advantage: finding new uses for FDA-approved drugs dramatically shortens the time to revenue compared to developing entirely new therapeutics from scratch. The regulatory pathway is shorter since safety has already been demonstrated.

The Young Founder Playbook

Wang’s background itself is noteworthy. He joined OpenAI in 2024 after dropping out of Harvard, where he was pursuing a bachelor’s degree in computer science. His move reflects a broader shift in venture capital: investors are increasingly comfortable backing young founders who haven’t completed traditional college education, particularly when their track records speak for themselves.

At OpenAI, Wang co-authored research papers exploring how AI models can automate and accelerate scientific discovery. That hands-on experience at the forefront of AI research appears to have positioned him well to tackle the intersection of artificial intelligence and drug development. It’s a market problem that affects millions and generates enormous returns for companies that crack it.

The broader narrative here extends beyond Wang’s individual departure. It reflects how tech talent concentrated at major AI companies is now splintering into focused startups, each tackling specific, high-value applications. OpenAI has become something of a talent incubator for the next generation of AI-focused ventures.

What’s Next

The race to build superior AI models for drug discovery will likely intensify. Investors see it as a multi-billion-dollar opportunity, and the recent funding announcements prove capital is flowing. Whether Wang’s startup succeeds will depend less on the size of its initial funding and more on whether his team can genuinely accelerate drug discovery in ways competitors can’t match.

The question isn’t whether AI will transform drug discovery. It almost certainly will. The real competition is about who builds the models that matter first.

Source: TechCrunch